You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Claims for Patent: 11,045,461


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,045,461
Title:Compositions of CXCR4 inhibitors and methods of preparation and use
Abstract:The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Inventor(s):Brands Karel Marie Joseph
Assignee:X4 PHARMACEUTICALS, INC.
Application Number:US16704302
Patent Claims: 2. The X4P-001 composition of claim 1 , wherein the amount of I-6 claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.3. The X4P-001 composition of claim 1 , wherein the amount of I-6 claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , is from about 0.01 to about 0.3% w/w of the X4P-001 composition.4. The X4P-001 composition of claim 1 , wherein the amount of I-6 is from 0.01 to 0.2% w/w of the X4P-001 composition.9. The X4P-001 composition of claim 8 , wherein the X4P-001 composition does not comprise I-2 or I-5 claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , in a detectable amount.10. The X4P-001 composition of claim 5 , wherein the amount of I-2 claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , is from about 0.01 to about 0.3% w/w of the X4P-001 composition.11. The X4P-001 composition of claim 6 , wherein the amount of I-3 claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.12. The X4P-001 composition of claim 8 , wherein the amount of I-3 claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.13. The X4P-001 composition of claim 7 , wherein the amount of I-5 claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , is from about 0.01 to about 0.4% w/w of the X4P-001 composition.14. The X4P-001 composition of claim 12 , wherein the amount of I-7 claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , is from about 0.01 to about 0.25% w/w of the X4P-001 composition.15. The X4P-001 composition of claim 14 , wherein the compound of formula I is present in the X4P-001 composition as a free base.16. The X4P-001 composition of claim 15 , wherein the composition comprises no more than 3.0% of total impurities.17. The X4P-001 composition of claim 16 , wherein the R-enantiomeric excess (% ee) of the compound of formula I is no less than 97.0%.18. The X4P-001 composition of claim 16 , wherein the total weight of I-6 and any additional impurities that are present comprise no more than about 0.8% w/w of the X4P-001 composition.19. A pharmaceutical composition comprising the X4P-001 composition according to claim 1 , and a pharmaceutically acceptable adjuvant claim 1 , carrier claim 1 , or vehicle.20. A pharmaceutical composition comprising the X4P-001 composition according to claim 15 , and a pharmaceutically acceptable adjuvant claim 15 , carrier claim 15 , or vehicle.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.